Pazdur R - Search Results

1

FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma.

Casak SJ, Marcus L, Fashoyin-Aje L, Mushti SL, Cheng J, Shen YL, Pierce WF, Her L, Goldberg KB, Theoret MR, Kluetz PG, Pazdur R, Lemery SJ. Casak SJ, et al. Among authors: pazdur r. Clin Cancer Res. 2021 Sep 1;27(17):4680-4684. doi: 10.1158/1078-0432.CCR-21-0557. Epub 2021 Apr 12. Clin Cancer Res. 2021. PMID: 33846198 Free PMC article. Clinical Trial.

2

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R. Bross PF, et al. Among authors: pazdur r. Clin Cancer Res. 2001 Jun;7(6):1490-6. Clin Cancer Res. 2001. PMID: 11410481

3

Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.

Cohen MH, Johnson JR, Li N, Chen G, Pazdur R. Cohen MH, et al. Among authors: pazdur r. Clin Cancer Res. 2002 Mar;8(3):665-9. Clin Cancer Res. 2002. PMID: 11895893

4

Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.

Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, U KM, Staten AM, Pazdur R. Cohen MH, et al. Among authors: pazdur r. Clin Cancer Res. 2002 May;8(5):935-42. Clin Cancer Res. 2002. PMID: 12006504

5

Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.

Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D, Pazdur R. Dagher R, et al. Among authors: pazdur r. Clin Cancer Res. 2002 Oct;8(10):3034-8. Clin Cancer Res. 2002. PMID: 12374669 Clinical Trial.

6

Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer.

Saad ED, Kraut EH, Hoff PM, Moore DF Jr, Jones D, Pazdur R, Abbruzzese JL. Saad ED, et al. Among authors: pazdur r. Am J Clin Oncol. 2002 Oct;25(5):451-3. doi: 10.1097/00000421-200210000-00005. Am J Clin Oncol. 2002. PMID: 12393982 Clinical Trial.

7

FDA drug approval summaries: fulvestrant.

Bross PF, Cohen MH, Williams GA, Pazdur R. Bross PF, et al. Among authors: pazdur r. Oncologist. 2002;7(6):477-80. doi: 10.1634/theoncologist.7-6-477. Oncologist. 2002. PMID: 12490735 Free article.

8

End points and United States Food and Drug Administration approval of oncology drugs.

Johnson JR, Williams G, Pazdur R. Johnson JR, et al. Among authors: pazdur r. J Clin Oncol. 2003 Apr 1;21(7):1404-11. doi: 10.1200/JCO.2003.08.072. J Clin Oncol. 2003. PMID: 12663734

9

Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.

Johnson JR, Bross P, Cohen M, Rothmann M, Chen G, Zajicek A, Gobburu J, Rahman A, Staten A, Pazdur R. Johnson JR, et al. Among authors: pazdur r. Clin Cancer Res. 2003 Jun;9(6):1972-9. Clin Cancer Res. 2003. PMID: 12796358 Clinical Trial.

10

Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.

Ibrahim A, Scher N, Williams G, Sridhara R, Li N, Chen G, Leighton J, Booth B, Gobburu JV, Rahman A, Hsieh Y, Wood R, Vause D, Pazdur R. Ibrahim A, et al. Among authors: pazdur r. Clin Cancer Res. 2003 Jul;9(7):2394-9. Clin Cancer Res. 2003. PMID: 12855610 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

603 results

Search Page

Filters